Metraipolis › archive › dc_eaa5bd68aab5

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study — Europe PMC PMID:42334369

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42334369
DOI
10.1111/bjh.70634
License (as archived)
solo-consultazione
Archived
2026-10-19T06:21:34.649Z
SHA-256 of the archived text
e929438f12dfc0d2a40beccf1557027a43c313e117defdffce912357951bb3ca
Stable URL of this page
https://metraipolis.com/documento/dc_eaa5bd68aab5

How to cite

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study — Europe PMC PMID:42334369 — Europe PMC (en), https://europepmc.org/article/MED/42334369 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eaa5bd68aab5 (Metraipolis archive dc_eaa5bd68aab5, sha256 e929438f12dfc0d2a40beccf1557027a43c313e117defdffce912357951bb3ca)
BibTeX
@misc{dceaa5bd68aab5,
  title = {Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study — Europe PMC PMID:42334369},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42334369},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eaa5bd68aab5; sha256 e929438f12dfc0d2a40beccf1557027a43c313e117defdffce912357951bb3ca},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42334369. Agents can read the archived copy with the MCP tool read_document.